Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|||
|
Press Release - BioSnate Pharmaceuticals, Inc. (BPAX-NASDAQ) |
|||
|
BioSante is a product development company. From the beginning, we have had our eye on women’s sexual health. Right now, we are developing a product, LibiGel®, for the treatment of female sexual dysfunction for which there is no product approved in the United States. We believe this represents a blockbuster opportunity. - Stephen M. Simes (BPAX) (Interview published March 11, 2011) |
||
The Most Powerful Name In Corporate News and Information. |
|||
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|||
BioSante Pharmaceuticals, Inc. To Present at JMP Securities Research Conference LINCOLNSHIRE, Illinois (May 4, 2011) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will be presenting at The JMP Securities Tenth Annual Research Conference. The event will take place from May 9, through May 11, 2011, at The Ritz-Carlton, San Francisco. Stephen M. Simes, BioSante's president & CEO, will speak on May 9, 2011 at 3:00 PM PT. He will provide an overview of the company, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program. A live audio webcast of Mr. Simes' remarks may be accessed at: http://www.wsw.com/webcast/jmp13/bpa/. The webcast will be archived approximately three hours after the live event and will be available for 90 days. About BioSante Pharmaceuticals, Inc. BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending with a PDUFA date of November 14, 2011, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: For more information, please contact:
|
|||
